To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news of Novacta Biosystems
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers
09-Aug-2012
Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total of 64 ...
DSM to manufacture C. difficile compound for Novacta Biosystems
18-Jun-2010
DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. DSM has successfully completed the process development and commenced ...
Novacta therapeutics and Oxygen Healthcare announce a multi FTE medicinal chemistry collaboration
14-Dec-2009
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years. “Following two very successful projects, we are excited to enter a third collaboration that combines ...
Cambridge Major To Partner with Novacta Biosystems
06-Apr-2009
Cambridge Major Laboratories and Novacta Biosystems have announced a collaboration combining respective expertise in process development, custom synthesis and biocatalysis. Novacta will develop biocatalytic approaches to target chiral intermediates which CML will then scale-up in facilities in ...
Novacta Therapeutics Strengthens Leadership Team
Dr David Pompliano Appointed to the Board of Directors and as Chairman of the Scientific Advisory Board
26-Feb-2009
Novacta Therapeutics Ltd announced the appointment of Dr David Pompliano to the Board of Directors. In addition to his role of non-executive director Dr. Pompliano will also provide strategic direction to Novacta’s R&D team and will hold the position of Chairman of the Scientific Advisory Board. ...
Novacta Therapeutics and UK Ministry of Defence Announce Collaboration to Discover Novel Antiviral Therapeutics
17-Nov-2008
Novacta Therapeutics announced that the UK's Defence Science and Technology Laboratory (DSTL) will evaluate its proprietary lantibiotics as a broad spectrum antiviral treatment. Novacta’s lantibiotics have demonstrated potential as antibiotics in early preclinical studies. These naturally ...
Novacta receives £3.5 million strategic translation award from the Wellcome trust ot target C. difficile infections
16-Jan-2008
Novacta Biosystems, a UK-based anti-infective therapeutics company, announced that the Wellcome Trust, the UK's largest medical research charity, has awarded it £3.5 million as part of the Trust's Strategic Translational Award programme. Novacta will use the award to progress development of a ...
Page 1 From 1
